A heater assembly for a vaporizer including a heat exchanger with an interior surface having at least one ridge and groove, and a heater positioned in the bore. An air management system for a vaporizer including a valve that allows air to be drawn through a valve inlet and pumped through a valve outlet with a pump or drawn through the valve outlet and inlet with external suction. A system and method for generating a workflow sequence for a vaporizer. The system and method including receiving task selections arranged in a task order, and generating a workflow sequence that is configured to instruct the vaporizer to sequentially perform the tasks associated with the task selections in the task order. A vaporizer that is configured to receive task selections arranged in a task order and sequentially perform the tasks associated with the task selections in the task order.
Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides high purity CBG, CBGA, and analogs thereof.
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
B01J 27/128 - HalogensCompounds thereof with iron group metals or platinum group metals
The present technology generally relates to Cannabis plants having increased cannabichromenic acid (CBCA) and/or cannabichromene (CBC) content as well as to nucleic acids related to same and methods of producing same.
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is —CH2CH═C(CH3)2, R2 is methyl, R3 is CsHn, R4 is —C(O)N(R4a)(R4b), R5 is H, R6 is OH, and R7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.
C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07C 233/92 - Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with at least one carbon atom of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07C 233/83 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 203/18 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07C 233/69 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
C07C 233/66 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
The present technology is in the field of molecular biology and plant biology, particularly as it pertains to gene editing in plants of the genus Cannabis. More specifically, there are provided systems and methods for targeted DNA modifications and gene editing in Cannabis plant, including systems and methods for making such modifications using a CRISPR/Cas-system nuclease complex, kits comprising the CRISPR/Cas-system nuclease complex, and constructs encoding the same.
Disclosed herein are methods for converting cannabidiol, cannabidiolic acid and analogs thereof into A8-tetrahydrocannabinol, A8-tetrahydrocannabinolic acid and analogs thereof. In particular, there is provided a method for converting a compound of Formula (I) as defined herein into a compound of Formula (II) as defined herein, the method comprising heating the compound of Formula (I) and a Lewis acidic heterogeneous reagent in an aprotic-solvent system to provide a compound of Formula (II), wherein the Lewis-acidic heterogeneous reagent is acidic alumina.
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
C07C 65/19 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
The synthesis of a range of pentylbezene-1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors. Accordingly, the use of such synthetic cannabinoids in the treatment of various disorders mediated by CB1 and CB2 is contemplated.
C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 309/75 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
C07C 317/22 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07D 205/06 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
C07D 207/408 - Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 277/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Disclosed are methods for synthesizing cannabielsoin (CBE) and or analogs thereof. In particular, the present disclosure provides methods for synthesizing CBE or analogs thereof comprising steps of providing a cannabinoid composition that comprises cannabidiol (CBD) or analogs thereof; combining the cannabinoid composition with an agent comprising a ketone functional group; and contacting the cannabinoid composition with an oxidizing agent or exposing the cannabinoid composition to electromagnetic radiation.
This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.
C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 69/16 - Acetic acid esters of dihydroxylic compounds
C07C 309/42 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
C07C 317/22 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07D 205/06 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
C07D 207/404 - 2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 277/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Disclosed herein are cannabinoid salt compounds formed by mixing an acidic cannabinoid compound with a base. According to embodiments of the present disclosure, the base is selected at least for having a low toxicity. Also disclosed are methods of preparing cannabinoid salt compounds. Further, the present disclosure provides use of the cannabinoid salt compounds as an intermediate for isolating an ultra-high purity cannabinoid from a cannabis plant material or extract thereof.
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
C07C 63/64 - Monocyclic acids with unsaturation outside the aromatic ring
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
C07C 35/14 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing six-membered rings with more than one hydroxy group bound to the ring
13.
METHODS FOR CONVERTING THC-RICH CANNABINOID MIXTURES INTO CBN-RICH CANNABINOID MIXTURES
Disclosed herein is a method of converting a THC-rich cannabinoid mixture that comprises at least about 20% THC into a CBN-rich cannabinoid mixture that comprises at least about 2.0% CBN. The method comprises contacting the cannabinoid mixture with a benzoquinone reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range; and (ii) a reaction time that is within a target reaction-time range, such that at least a portion of the of the THC in the THC-rich cannabinoid mixture is converted into CBN.
Water-soluble compositions including cannabinoids for use in beverages and foods, methods of preparing the compositions, and methods of preparing beverages and foods including the compositions are disclosed herein. The compositions comprise at least one cannabinoid, at least one saccharide, at least one surfactant, and at least one carrier oil.
A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
A23L 29/10 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing emulsifiers
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.
C07C 43/315 - Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
C07C 69/96 - Esters of carbonic or haloformic acids
C07C 69/28 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07C 43/305 - Compounds having groups having acetal carbon atoms as ring members or bound to carbon atoms of rings other than six-membered aromatic rings
16.
Methods of synthesizing cannabigerol, cannabigerolic acid, and analogs thereof
Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
B01J 27/128 - HalogensCompounds thereof with iron group metals or platinum group metals
The present application discloses a compound of formula (I), compositions comprising said compound, and a method of using said compound as a cannabinoid receptor ligand in the treatment or prevention of diseases associated with a cannabinoid receptor, such as, CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR119, TRPV1, TPRV2, PPARγ or a μ-opioid receptor.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
31 - Agricultural products; live animals
32 - Beers; non-alcoholic beverages
34 - Tobacco; smokers' articles
35 - Advertising and business services
36 - Financial, insurance and real estate services
39 - Transport, packaging, storage and travel services
40 - Treatment of materials; recycling, air and water treatment,
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Cannabis for use in the manufacture of animal foodstuffs, not medicinal; cannabis for use in the manufacture of food products, not medicinal; derivatives of cannabis for use in the manufacture of animal foodstuffs, not medicinal; derivatives of cannabis for use in the manufacture of food products, not medicinal.
(2) Bar and liquid soaps containing cannabis; bath additives containing cannabis; beauty care cosmetics containing cannabis; body and beauty care cosmetics containing cannabis; body and beauty care cosmetics containing cannabis derivatives; body creams containing cannabis; cannabis oil for cosmetic purposes; cannabis oil for toiletry purposes; cannabis-based cosmetics; cosmetics containing cannabis; cosmetics containing cannabis derivatives; non- medicated skin care and toiletry preparations containing cannabis, namely, oils, ointments, serums, salves, balms, creams, lotions, gels, toners, cleaners, peels, and roll-on sticks; skin care preparations containing cannabis; topical skin creams containing derivatives of cannabis.
(3) Bar and liquid soaps containing cannabis for medicinal purposes; bath additives containing cannabis for medicinal purposes; body creams containing cannabis for medicinal purposes; cannabis capsules as a sleep aid; cannabis capsules for maintaining general health and well-being; cannabis capsules for management of opioid addiction; cannabis capsules for medicinal purposes; cannabis capsules for mood enhancement; cannabis capsules for pain management; cannabis capsules for reducing anxiety; cannabis capsules for reducing stress; cannabis capsules for temporary relief of seizures; cannabis capsules for the relief of epilepsy; cannabis capsules for the relief of nausea; cannabis capsules for the relief of nausea caused by chemotherapy; cannabis capsules for the relief of nerve pain; cannabis capsules for the treatment of muscle spasms caused by multiple sclerosis; cannabis concentrates for temporary relief of seizures; cannabis concentrates for the relief of nausea caused by chemotherapy; cannabis concentrates for the relief of nerve pain; cannabis for medical purposes; cannabis oil as a sleep aid; cannabis oil for maintaining general health and well-being; cannabis oil for management of opioid addiction; cannabis oil for medicinal purposes; cannabis oil for mood enhancement; cannabis oil for pain management; cannabis oil for reducing anxiety; cannabis oil for reducing stress; cannabis oil for the relief of epilepsy; cannabis oil for the relief of nausea; cannabis oil for the treatment of cancer; cannabis salve for reducing pain and inflammation; cannabis salve for treatment of arthritis; cannabis salve for treatment of eczema; cannabis salve for treatment of psoriasis; cannabis salves for medicinal purposes; cannabis-infused drinks for medical purposes; cannabis-infused effervescent tablets for medical purposes; cannabis-infused foods for medical purposes; cured cannabis buds for medical purposes; dietary pet supplements containing cannabis in the form of pet treats and pet food; dietary supplements for animals containing cannabis derivatives for medicinal purposes; dietary supplements for animals containing cannabis for medicinal purposes; dietary supplements for humans containing cannabis derivatives for recreational purposes; dietary supplements for humans containing cannabis derivatives for medicinal purposes; dietary supplements for humans containing cannabis for medicinal purposes; dietary supplements for humans containing cannabis for recreational purposes; dietetic food and substances adapted for medical and veterinary use containing cannabis; dried cannabis buds for medical purposes; gummy vitamins containing cannabis derivatives for recreational purposes; gummy vitamins containing cannabis derivatives for medicinal purposes; gummy vitamins containing cannabis for medicinal purposes; gummy vitamins containing cannabis for recreational purposes; marijuana for medical purposes; marijuana oil for reducing anxiety; marijuana oil for the relief of nausea; medical cannabis for the relief of nausea; medical cannabis in the form of capsules that facilitate the delivery of drugs; medical cannabis in the form of dermal patches that facilitate the delivery of drugs; medical cannabis in the form of dermal sprays that facilitate the delivery of drugs; medical cannabis in the form of herbal teas; medical cannabis in the form of herbal teas for medicinal purposes; medical cannabis in the form of lozenges that facilitate the delivery of drugs; medical cannabis in the form of oils to facilitate the delivery of drugs; medical cannabis in the form of oral sprays that facilitate the delivery of drugs; medical cannabis in the form of tinctures that facilitate the delivery of drugs; medicated cosmetics containing cannabis; medicated cosmetics containing cannabis derivatives; medicated skin care and toiletry preparations containing cannabis, namely, oils, ointments, serums, salves, balms, creams, lotions, gels, toners, cleaners, peels, and roll-on sticks; medicinal cannabis; medicinal cannabis as a sleep aid; medicinal cannabis for management of opioid addiction; medicinal cannabis for mood enhancement; medicinal cannabis for pain management; medicinal cannabis for reducing anxiety; medicinal cannabis for reducing stress; medicinal cannabis for temporary relief of seizures; medicinal cannabis for the relief of epilepsy; medicinal cannabis for the relief of nausea caused by chemotherapy; medicinal cannabis for the relief of nerve pain; medicinal cannabis for the treatment of muscle spasms caused by multiple sclerosis; nutraceuticals containing cannabis as a sleep aid; nutraceuticals containing cannabis for maintaining general health and well being; nutraceuticals containing cannabis for management of opioid addiction; nutraceuticals containing cannabis for reducing stress and fatigue; nutraceuticals containing cannabis for relieving depression; nutraceuticals containing cannabis for the relief of epilepsy; nutraceuticals containing cannabis for the relief of pain; nutritional supplemental meal replacement bars containing cannabis; nutritional supplemental meal replacement bars containing cannabis derivatives; Nutritional supplements containing cannabis derivatives for medicinal purposes; nutritional supplements containing cannabis derivatives for recreational purposes; nutritional supplements containing cannabis for medicinal purposes; Nutritional supplements containing cannabis for recreational purposes; nutritional supplements containing cannabis, namely, oral sprays, tinctures, gummies, and recovery shots for medicinal purposes; nutritional supplements containing cannabis, namely, oral sprays, tinctures, gummies, and recovery shots for recreational purposes; oral sprays containing cannabis as a sleep aid; oral sprays containing cannabis for maintaining general health and wellbeing; oral sprays containing cannabis for management of opioid addiction; oral sprays containing cannabis for mood enhancement; oral sprays containing cannabis for reducing stress and fatigue; oral sprays containing cannabis for relaxation; oral sprays containing cannabis for relieving anxiety; oral sprays containing cannabis for relieving depression; oral sprays containing cannabis for the relief of epilepsy; oral sprays containing cannabis for the relief of pain; pills, tablets, sublingual doses and dissolvable strips containing cannabis for maintaining general health and well-being; skin care preparations containing cannabis for medicinal purposes; smoking cannabis for medical purposes; topical skin creams containing derivatives of cannabis for medicinal purposes; transdermal patches containing cannabis as a sleep aid; transdermal patches containing cannabis for maintaining general health and well being; transdermal patches containing cannabis for management of opioid addiction; transdermal patches containing cannabis for reducing stress and fatigue; transdermal patches containing cannabis for relaxation; transdermal patches containing cannabis for relieving anxiety; transdermal patches containing cannabis for relieving depression; transdermal patches containing cannabis for the relief of epilepsy; transdermal patches containing cannabis for the relief of pain; vaping cannabis for medical purposes; vaporized cannabis for medical purposes; vitamin preparations containing cannabis derivatives for medicinal purposes; vitamin preparations containing cannabis derivatives for recreational purposes; vitamin preparations containing cannabis for medicinal purposes; vitamin preparations containing cannabis for recreational purposes.
(4) Electronic publications, namely, newsletters, brochures, reports and guides in the field of cannabis.
(5) Humidity packs of paper for cannabis packaging; humidity packs of plastic for cannabis packaging; printed publications in the field of cannabis; printed publications, namely, newsletters, brochures, reports and guides in the field of cannabis.
(6) Cannabis oil for food; cannabis oil for human consumption; edible oils and resins derived from cannabis; edible oils containing cannabis; edible oils containing cannabis derivatives; fruit-based snack food containing cannabis; fruit-based snack food containing cannabis derivatives; gluten-free snack food containing cannabis; gluten-free snack food containing cannabis derivatives; jams containing cannabis; jams containing cannabis derivatives; nut-based snack food containing cannabis; nut-based snack food containing cannabis derivatives; vegetable-based snack food containing cannabis; vegetable-based snack food containing cannabis derivatives.
(7) Baked goods being brownies, cakes, pastries, doughnuts, muffins, cupcakes and cookies all containing cannabis; biscuits containing cannabis; breakfast cereals containing cannabis; breakfast cereals containing derivatives of cannabis; brownies containing cannabis; cakes containing cannabis; candy containing cannabis; cannabis-based, cannabinoid-based, cannabis-infused and cannabinoid-infused candy; cereal bars containing cannabis; cereal-based snack foods containing cannabis; cereal-based snack foods containing derivatives of cannabis; chewing gum containing cannabis; chocolate bars infused with cannabis; chocolate confectionery containing cannabis; chocolate confectionery containing derivatives of cannabis; chocolate containing cannabis; chocolate containing derivatives of cannabis; coffee-based beverages containing cannabis; coffee-based beverages containing derivatives of cannabis; cookies containing cannabis; corn-based snack foods containing cannabis; corn-based snack foods containing derivatives of cannabis; cupcakes containing cannabis; energy bars containing cannabis; energy bars containing cannabis derivatives; flour containing cannabis; flour containing cannabis derivatives; grain-based snack foods containing cannabis; grain-based snack foods containing derivatives of cannabis; granola-based snack foods containing cannabis; granola-based snack foods containing derivatives of cannabis; honey infused with cannabis; muffins containing cannabis; rice-based snack foods containing cannabis; rice-based snack foods containing derivatives of cannabis; sugar confectionery containing cannabis; sugar confectionery containing derivatives of cannabis; tea-based beverages containing cannabis; tea-based beverages containing derivatives of cannabis; teas infused with cannabis; wheat-based snack foods containing cannabis; wheat-based snack foods containing derivatives of cannabis.
(8) Cannabis oil for animal consumption; cannabis oil for animal consumption, not medicinal; cannabis seeds for agricultural purposes; cannabis, unprocessed; edible pet treats containing cannabis, not medicinal; edible pet treats containing derivatives of cannabis, not medicinal; foodstuffs for animals containing cannabis, not medicinal; foodstuffs for animals containing derivatives of cannabis, not medicinal; fresh cannabis; live cannabis plants; pet food containing cannabis, not medicinal; pet food containing derivatives of cannabis, not medicinal.
(9) Beer infused with cannabis; beer-flavoured beverage infused with cannabis; beer-flavoured beverage infused with marijuana; bottled water containing cannabis; bottled water containing derivatives of cannabis; cannabis-based tinctures for adding to beverages, not medicinal; cannabis-based tinctures for adding to non-alcoholic beverages, not medicinal; carbonated beverages infused with cannabis; carbonated soft drinks containing derivatives of cannabis; carbonated soft drinks infused with cannabis oil; cider flavoured beverages infused with cannabis; energy drinks containing cannabis; energy drinks containing derivatives of cannabis; energy drinks infused with cannabis oil; flavored waters containing cannabis; flavored waters containing derivatives of cannabis; fruit beverages and fruit juices containing cannabis; fruit beverages and fruit juices containing derivatives of cannabis; fruit beverages containing derivatives of cannabis; fruit drinks and juices infused with cannabis oil; fruit juices containing derivatives of cannabis; fruit-based beverages containing cannabis; fruit-based beverages containing derivatives of cannabis; fruit-flavoured beverages infused with cannabis; honey-based beverages infused with cannabis; iced fruit beverages infused with cannabis oil; mineral and aerated waters containing cannabis; mineral and aerated waters containing derivatives of cannabis; powder containing cannabis used in the preparation of energy drinks; powder containing cannabis used in the preparation of flavored waters; powder containing cannabis used in the preparation of fruit juices; powder containing cannabis used in the preparation of fruit-based drinks; powder containing cannabis used in the preparation of soft drinks; powder containing cannabis used in the preparation of sports drinks; powder containing derivatives of cannabis used in the preparation of energy drinks; powder containing derivatives of cannabis used in the preparation of flavored waters; powder containing derivatives of cannabis used in the preparation of fruit juices; powder containing derivatives of cannabis used in the preparation of fruit-based drinks; powder containing derivatives of cannabis used in the preparation of soft drinks; powder containing derivatives of cannabis used in the preparation of sports drinks; protein enriched sports beverages infused with cannabis; smoothies containing cannabis; smoothies containing derivatives of cannabis; sports drinks containing cannabis; sports drinks containing derivatives of cannabis; vegetable-based beverages containing cannabis; vegetable-based beverages containing derivatives of cannabis; wine flavoured beverages infused with cannabis.
(10) Cannabis cigarettes; cannabis distillate; cannabis for recreational use, for smoking; cannabis for recreational use, for vaporizing; cannabis for smoking; cannabis grinders; cannabis oil for electronic cigarettes; cannabis oil for oral vaporizers for smoking; cannabis rolling trays; cannabis-derived resins and oils for recreational use, for smoking; cannabis-derived resins and oils for recreational use, for vaporizing; dabbing dishes being dab rigs for smoking cannabis purposes; derivatives of cannabis, namely resins and oils, for oral vaporizers for smoking; dried cannabis; electronic cigarette liquid (e-liquid) comprised of flavorings in liquid form containing cannabis; electronic cigarette liquid (e-liquid) comprised of flavorings in liquid form containing derivatives of cannabis; electronic cigarettes containing cannabis oil; milled cannabis for smoking; odour-proof travel cases and jars for storing cannabis; oral vaporizer cartridges sold filled with electronic cigarette liquid (e-liquid) flavorings containing cannabis; rolling papers for cannabis cigarettes; rolling trays for dried tobacco and cannabis; smokers' articles, namely, pouches for use with marijuana and cannabis; smokers' articles, namely, smoking pipes for use with marijuana and cannabis; vaping pens for smoking purposes containing cannabis. (1) Advertising services, namely providing ratings on products and services for commercial purposes posted by users in the field of marijuana and cannabis via a website; advertising services, namely providing recommendations on products and services for commercial purposes posted by users in the field of marijuana and cannabis via a website; advertising services, namely providing reviews on products and services for commercial purposes posted by users in the field of marijuana and cannabis via a website; distributorship in the field of cannabis; online sale of dried marijuana and cannabis for ingestion; online sale of dried marijuana and cannabis for smoking; online sale of dried marijuana and cannabis recreational consumption; providing the ratings, reviews and recommendations on products and services via a website for commercial purposes posted by users in the field of cannabis; public relations services in the field of cannabis; retail sale and online sale of cannabis; retail sale and online sale of cannabis derivatives; retail sale and online sale of cannabis oils; retail sale and online sale of cannabis seeds; retail sale and online sale of cannabis tisanes; retail sale and online sale of food products containing cannabis; retail sale of cannabis; retail sale of cannabis smoking accessories; retail sale of derivatives of cannabis; retail sale of dried marijuana and cannabis for smoking; retail sale of dried marijuana and cannabis recreational consumption; retail store services featuring cannabis cigarettes, cannabis for smoking, cannabis grinders, cannabis oil for electronic cigarettes, cannabis oil for oral vaporizers for smoking, cigarette lighters, dried cannabis; wholesale sales of cannabis; wholesale sales of derivatives of cannabis.
(2) Financial investment in the cannabis industry.
(3) Delivery of products containing cannabis; delivery of products containing derivatives of cannabis; packaging of cannabis; packaging of derivatives of cannabis; packaging of natural health products containing cannabis; providing the delivery of cannabis, cannabis-related products, derivatives of cannabis and natural health products containing cannabis by mail order, by hand, by courier, by train, by truck and by air; providing the packaging of cannabis, cannabis-related products, derivatives of cannabis and natural health products containing cannabis.
(4) Custom production of cannabis for medical purposes; custom production of cannabis for others; processing of cannabis; processing of cannabis for medical purposes.
(5) Education and counseling services, namely, providing advisory and counseling services in the field of cannabis education; educational services in the field of cannabis; electronic publications provided online in the field of marijuana and cannabis; production of instructional videos in the field of cannabis treatment; providing educational information in the field of cannabis via a website; providing entertainment news and educational information in the field of cannabis and cannabis culture via a website; providing news via a website in the nature of current event reporting in the field of cannabis and cannabis culture; training of persons in establishments and facilities in the field of marijuana and cannabis; training of persons in the management and operation of retail stores in the field of marijuana and cannabis; workshops, seminars, classes and lectures in the fields of the uses of cannabis for personal health and well-being, and the cultivation and processing of cannabis plants.
(6) Development of cannabis products for clinical studies; lab testing of cannabis plants; product development services in the field of cannabis and marijuana; scientific research and development in the engineering, breeding and genetically modifying cannabis; scientific research and development in the field of cannabis; scientific research and development of product packaging for cannabis and marijuana; scientific research and development services for the identification of cannabis specific diseases; scientific research in the area of cannabis products, namely, medical cannabis, cannabis for recreational use, derivatives of cannabis, and natural health products containing cannabis; scientific research in the field of cannabis; software as a service (SaaS), namely providing temporary use of on-line non-downloadable software to allow users to track and analyze consumer consumption of cannabis for medical purposes.
(7) Consulting and advisory services in the field of cannabis for medical purposes; consulting services in the field of medical use of cannabis; cultivation and breeding of cannabis for medical purposes; cultivation of marijuana and cannabis; growing, cultivating, breeding and harvesting cannabis; growing, cultivating, breeding and harvesting cannabis seeds; informational services, namely an informational service whereby medical cannabis patients can obtain product information about medical cannabis using a smartphone device; medical cannabis dispensary services; medical counselling services in the field of cannabis; medical counselling services in the field of cannabis oils; operation and management of a medical cannabis dispensary; providing indications and effects of particular cannabis strains via a website; providing the breeding, growing, cultivation, harvesting and production of cannabis.
A method of compacting a smokeable product in a cone for production of smoking articles is disclosed. The method includes aligning a respective cone held in a cone pallet with a pin. The cone contains a volume of the smokeable product and has an open upper end. The method further includes advancing the pin into the volume of the smokeable product through the open upper end of the cone; and withdrawing the pin from the volume of the smokeable product. The volume of the smokeable product has an empty column formed therein when the pin is withdrawn. The method further includes vibrating the cone pallet to induce collapse of the smokeable product into the column.
The present technology is in the field of plant breeding and genetics, particularly as it pertains to the genus Cannabis. More specifically, there are provided methods and compositions for producing a population of Cannabis plants with enhanced resistance to powdery mildew. The methods use the detection of molecular genetic markers linked to powdery mildew resistance loci to select for plants displaying an enhanced powdery mildew resistance phenotype.
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
This disclosure relates to cannabinoid derivatives of Formula (I), wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the cannabinoid derivatives. These compounds are potential cannabinoid receptor inhibitors, including CB1 and CB2 receptors.
C07C 235/60 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 235/58 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring
C07C 235/88 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having the nitrogen atom of at least one of the carboxamide groups further acylated
C07C 235/62 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 235/64 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 203/18 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07C 255/29 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
C07C 271/34 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 271/48 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
C07C 271/24 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 233/60 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 233/18 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Compositions having enhanced cannabicyclol (CBL) or CBL derivative concentrations are disclosed herein as are methods of synthesizing CBL and CBL derivative in high-purity form. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid extracts, isolates and/or distillates; (iii) provide CBL and/or CBL derivative at higher yield; (iv) provide easier methods to purify product mixtures comprising CBL and/or CBL derivative; (v) provide product mixtures that comprise unique ratios of CBL or CBL derivative relative to other cannabinoids; (vi) provide product mixtures with reduced THC concentrations and/or (vii) provide artificial resins having of a mixture cannabinoids that cannot be produced by extracting cannabis plant material.
This disclosure relates generally to cannabinoid derivatives having the formula (I), wherein R4 is hydrogen, —C(Q1)N(R4a)(R4b) or —C(R4J)(R4k)N(R4e)C(0)R4f, R6 is hydrogen, —C(Q2)N(R6a)(R6b) or —C(R6J)(R6k)N(R6e)C(0)R6f, provided that R6 is not hydrogen when R4 is hydrogen. Pharmaceutical compositions for the prevention or treatment of a disease associated with a cannabinoid receptor (such as CB1 or CB2) in a subject in need thereof, and methods of using the cannabinoid derivatives are also described.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
24.
SEPARATION OF CANNABINOIDS FROM MIXTURES THEREOF BY EXTRACTION AND DISTILLATION
The present disclosure relates to isolating one or more cannabinoids from an input mixture. There is disclosed an apparatus that comprises a mixing vessel, a volatizing unit, and a distillation unit. The mixing vessel combines a first input mixture and a high boiling-point carrier agent to generate a second input mixture. The volatizing unit volatilizes cannabinoids from the second input mixture for separating the mixture into a cannabinoid-containing vapor stream and a residue. The distillation unit receives the cannabinoid-containing vapor stream and separates a first cannabinoid from at least a second cannabinoid. There are also disclosed methods that comprise the steps of combining a first input mixture with a high boiling-point carrier agent to provide a second input mixture, volatilizing the second input mixture into a vapor stream containing one or more cannabinoids and a residue, and separating a first cannabinoid from a second in the distillation unit.
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.
C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
C07C 43/225 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
C07C 255/53 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
C07D 203/10 - Radicals substituted by singly bound oxygen atoms
C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
C07D 209/12 - Radicals substituted by oxygen atoms
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 263/14 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
C07D 271/113 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 277/26 - Radicals substituted by sulfur atoms
C07D 295/033 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
C07D 303/14 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
C07D 309/32 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
C07D 333/16 - Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
C07D 333/56 - Radicals substituted by oxygen atoms
C07D 473/00 - Heterocyclic compounds containing purine ring systems
26.
CANNABICHROMENE COMPOSITIONS AND METHODS OF SYNTHESIZING CANNABICHROMENE
Compositions having enhanced cannabichromene (CBC) and abnormal cannabichromene (CBCab) concentrations are disclosed herein as are methods of synthesizing CBC and CBCab. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) provide product mixtures with enhanced CBCab concentrations; (iii) provide CBC at higher yield; (iv) provide easier to purify product mixtures comprising CBC; (v) provide product mixtures that comprise unique ratios of CBCab relative to other cannabinoids; and/or (vi) provide product mixtures with reduced THC concentrations.
Disclosed herein are compositions comprising an oil having at least one cannabinoid and at least one solid powder and methods of making and using the same. In one embodiment, the compositions disclosed herein are suitable for making cannabinoid containing tablets by pressing a composition of this disclosure with one or more formulating agents, such as binders, fillers, bulking agents, excipients, etc.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present technology is in the field of plant breeding and genetics, particularly as it pertains to the genus Cannabis. More specifically, there are provided methods and compositions for producing a population of Cannabis plants with enhanced resistance to powdery mildew. The methods use the detection of molecular genetic markers linked to powdery mildew resistance loci to select for plants displaying an enhanced powdery mildew resistance phenotype.
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
34 - Tobacco; smokers' articles
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: oral sprays (not for medical use) and creams (not for medical use). Medical cannabis and marijuana; dried medicinal cannabis; edible medicinal cannabis; fresh medicinal cannabis; medical cannabis and marijuana derivatives; terpenes, terpenoids, cannabidiol, and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, sprays, waxes, topicals, tonics, creams, pomades, ointments, capsules, patches, tablets, tinctures, suppositories, and balms, all for medical purposes; cannabis concentrates for medical purposes; cannabis extract for medical purposes; cannabis topicals for medical purposes; edible cannabis for medical purposes; pharmaceuticals derived from cannabis; herbal and dietary supplements derived from cannabis; botanical supplements derived from cannabis; nutraceuticals; hemp protein powder dietary supplements; cannabis topicals. Edible oils; edible oils containing medicinal marijuana, marijuana, and cannabis, and derivatives thereof; edible butters containing medicinal marijuana, marijuana, and cannabis and derivatives thereof; edible butters; edible butter and edible fat containing hemp and hemp extracts; edible butters and edible fats containing cannabidiol and cannabinoids derived from hemp; hemp hearts processed; hemp oil; hemp seeds; hemp milk. Hemp flour; hemp cereal; grain and cereal based snack foods, namely, hemp-based snack foods; hemp-based processed grains and cereals; processed hemp seeds. Dried cannabis; fresh cannabis; cannabis extracts; cannabis concentrates; cannabis for smoking purposes; cannabis derivatives; terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils; hemp, hemp extracts, cannabidiol and cannabinoids derived from hemp for smoking and ingestion. Wholesale, retail sale and online sale of medical cannabis and marijuana, dried medicinal cannabis, edible medicinal cannabis, and fresh medicinal cannabis; wholesale, retail sale and online sale of medical cannabis and marijuana derivatives, namely terpenes, terpenoids, cannabidiols, and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, sprays, waxes, topicals, tonics, creams, pomades, ointments, capsules, patches, tablets, tinctures, suppositories, and balms, all for medical purposes; wholesale, retail sale and online sale of herbal and dietary supplements derived from cannabis, botanical supplements derived from cannabis, pharmaceuticals derived from cannabis, edible cannabis for medical purposes, cannabis topicals for medical purposes, cannabis extract for medical purposes, cannabis concentrates for medical purposes; wholesale, retail sale and online sale of dried cannabis, fresh cannabis, cannabis extracts, cannabis topicals, cannabis concentrates and edible cannabis; wholesale, retail sale and online sale of cannabis derivatives, namely terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, oral sprays, topical, capsules, tablets, tinctures, and creams; wholesale, retail sale and online sale of health food supplements derived from hemp, pharmaceuticals derived from hemp, nutraceuticals, botanical supplements for general health and well-being, herbal supplements for general health and well-being, natural health food products derived from hemp; wholesale, retail sale and online sale of nutraceuticals, nutritional supplements derived from hemp, namely hemp oil, shelled hemp seeds, and hemp protein powder; wholesale, retail sale and online sale of hemp derivatives, namely cannabidiol and cannabinoids; wholesale, retail sale and online sale of herbal extracts for medicinal purposes; wholesale, retail sale and online sale of hemp, hemp extracts, hemp fibres, cannabidiol and cannabinoids derived from hemp. Medical education in the field of medicinal cannabis; medical education in the field of hemp for medical purposes; medical patient education in the field of medical cannabis; medical education in the field of pharmaceuticals and health supplements. Medical counselling in the field of medical cannabis; medical counselling in the field of hemp for medical purposes; providing medical information in the field of medical marijuana, marijuana, cannabis, hemp, cannabidiol, and cannabinoids via a website; medical counselling in the field of natural health foods and nutraceuticals; providing information in the field of hemp for medical purposes via a website.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
34 - Tobacco; smokers' articles
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: oral sprays (not for medical use) and creams (not for medical use). Medical cannabis and marijuana; dried medicinal cannabis; edible medicinal cannabis; fresh medicinal cannabis; medical cannabis and marijuana derivatives; terpenes, terpenoids, cannabidiol, and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, sprays, waxes, topicals, tonics, creams, pomades, ointments, capsules, patches, tablets, tinctures, suppositories, and balms, all for medical purposes; cannabis concentrates for medical purposes; cannabis extract for medical purposes; cannabis topicals for medical purposes; edible cannabis for medical purposes; pharmaceuticals derived from cannabis; herbal and dietary supplements derived from cannabis; botanical supplements derived from cannabis; nutraceuticals; hemp protein powder dietary supplements; cannabis topicals. Edible oils; edible oils containing medicinal marijuana, marijuana, and cannabis, and derivatives thereof; edible butters containing medicinal marijuana, marijuana, and cannabis and derivatives thereof; edible butters; edible butter and edible fat containing hemp and hemp extracts; edible butters and edible fats containing cannabidiol and cannabinoids derived from hemp; hemp hearts processed; hemp oil; hemp seeds; hemp milk. Hemp flour; hemp cereal; grain and cereal based snack foods, namely, hemp-based snack foods; hemp-based processed grains and cereals; processed hemp seeds. Dried cannabis; fresh cannabis; cannabis extracts; cannabis concentrates; cannabis for smoking purposes; cannabis derivatives; terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils; hemp, hemp extracts, cannabidiol and cannabinoids derived from hemp for smoking and ingestion. Wholesale, retail sale and online sale of medical cannabis and marijuana, dried medicinal cannabis, edible medicinal cannabis, and fresh medicinal cannabis; wholesale, retail sale and online sale of medical cannabis and marijuana derivatives, namely terpenes, terpenoids, cannabidiols, and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, sprays, waxes, topicals, tonics, creams, pomades, ointments, capsules, patches, tablets, tinctures, suppositories, and balms, all for medical purposes; wholesale, retail sale and online sale of herbal and dietary supplements derived from cannabis, botanical supplements derived from cannabis, pharmaceuticals derived from cannabis, edible cannabis for medical purposes, cannabis topicals for medical purposes, cannabis extract for medical purposes, cannabis concentrates for medical purposes; wholesale, retail sale and online sale of dried cannabis, fresh cannabis, cannabis extracts, cannabis topicals, cannabis concentrates and edible cannabis; wholesale, retail sale and online sale of cannabis derivatives, namely terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, oral sprays, topical, capsules, tablets, tinctures, and creams; wholesale, retail sale and online sale of health food supplements derived from hemp, pharmaceuticals derived from hemp, nutraceuticals, botanical supplements for general health and well-being, herbal supplements for general health and well-being, natural health food products derived from hemp; wholesale, retail sale and online sale of nutraceuticals, nutritional supplements derived from hemp, namely hemp oil, shelled hemp seeds, and hemp protein powder; wholesale, retail sale and online sale of hemp derivatives, namely cannabidiol and cannabinoids; wholesale, retail sale and online sale of herbal extracts for medicinal purposes; wholesale, retail sale and online sale of hemp, hemp extracts, hemp fibres, cannabidiol and cannabinoids derived from hemp. Medical education in the field of medicinal cannabis; medical education in the field of hemp for medical purposes; medical patient education in the field of medical cannabis; medical education in the field of pharmaceuticals and health supplement. Medical counselling in the field of medical cannabis; medical counselling in the field of hemp for medical purposes; providing medical information in the field of medical marijuana, marijuana, cannabis, hemp, cannabidiol, and cannabinoids via a website; medical counselling in the field of natural health foods and nutraceuticals; providing information in the field of hemp for medical purposes via a website.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
34 - Tobacco; smokers' articles
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: oral sprays (not for medical use) and creams (not for medical use). Medical cannabis and marijuana; dried medicinal cannabis; edible medicinal cannabis; fresh medicinal cannabis; medical cannabis and marijuana derivatives; terpenes, terpenoids, cannabidiol, and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, sprays, waxes, topicals, tonics, creams, pomades, ointments, capsules, patches, tablets, tinctures, suppositories, and balms, all for medical purposes; cannabis concentrates for medical purposes; cannabis extract for medical purposes; cannabis topicals for medical purposes; edible cannabis for medical purposes; pharmaceuticals derived from cannabis; herbal and dietary supplements derived from cannabis; botanical supplements derived from cannabis; nutraceuticals; hemp protein powder dietary supplements; cannabis topicals. Edible oils; edible oils containing medicinal marijuana, marijuana, and cannabis, and derivatives thereof; edible butters containing medicinal marijuana, marijuana, and cannabis and derivatives thereof; edible butters; edible butter and edible fat containing hemp and hemp extracts; edible butters and edible fats containing cannabidiol and cannabinoids derived from hemp; hemp hearts processed; hemp oil; hemp seeds; hemp milk. Hemp flour; hemp cereal; grain and cereal based snack foods, namely, hemp-based snack foods; hemp-based processed grains and cereals; processed hemp seeds. Dried cannabis; fresh cannabis; cannabis extracts; cannabis concentrates; cannabis for smoking purposes; cannabis derivatives; terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils; hemp, hemp extracts, cannabidiol and cannabinoids derived from hemp for smoking and ingestion. Wholesale, retail sale and online sale of medical cannabis and marijuana, dried medicinal cannabis, edible medicinal cannabis, and fresh medicinal cannabis; wholesale, retail sale and online sale of medical cannabis and marijuana derivatives, namely terpenes, terpenoids, cannabidiols, and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, sprays, waxes, topicals, tonics, creams, pomades, ointments, capsules, patches, tablets, tinctures, suppositories, and balms, all for medical purposes; wholesale, retail sale and online sale of herbal and dietary supplements derived from cannabis, botanical supplements derived from cannabis, pharmaceuticals derived from cannabis, edible cannabis for medical purposes, cannabis topicals for medical purposes, cannabis extract for medical purposes, cannabis concentrates for medical purposes; wholesale, retail sale and online sale of dried cannabis, fresh cannabis, cannabis extracts, cannabis topicals, cannabis concentrates and edible cannabis; wholesale, retail sale and online sale of cannabis derivatives, namely terpenes, terpenoids, cannabidiol and cannabinoids in the following presentations: concentrates, hashes, resins, shatter, oils, oral sprays, topical, capsules, tablets, tinctures, and creams; wholesale, retail sale and online sale of health food supplements derived from hemp, pharmaceuticals derived from hemp, nutraceuticals, botanical supplements for general health and well-being, herbal supplements for general health and well-being, natural health food products derived from hemp; wholesale, retail sale and online sale of nutraceuticals, nutritional supplements derived from hemp, namely hemp oil, shelled hemp seeds, and hemp protein powder; wholesale, retail sale and online sale of hemp derivatives, namely cannabidiol and cannabinoids; wholesale, retail sale and online sale of herbal extracts for medicinal purposes; wholesale, retail sale and online sale of hemp, hemp extracts, hemp fibres, cannabidiol and cannabinoids derived from hemp. Medical education in the field of medicinal cannabis; medical education in the field of hemp for medical purposes; medical patient education in the field of medical cannabis; medical education in the field of pharmaceuticals and health supplements. Medical counselling in the field of medical cannabis; medical counselling in the field of hemp for medical purposes; providing medical information in the field of medical marijuana, marijuana, cannabis, hemp, cannabidiol, and cannabinoids via a website; medical counselling in the field of natural health foods and nutraceuticals; providing information in the field of hemp for medical purposes via a website.
32.
METHODS FOR REDUCING THC CONTENT IN COMPLEX CANNABINOID MIXTURES IN WHICH THC IS A MINOR COMPONENT
Disclosed herein is a method for upgrading a cannabinoid mixture that comprises tetrahydrocannabinol (THC) and one or more non-THC cannabinoids, when the cannabinoid mixture has a THC content of less than about 20 wt. %. The method comprises contacting the cannabinoid mixture with a benzoquinone reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range for the benzoquinone reagent and the cannabinoid mixture; and (ii) a reaction time that is within a target reaction-time range for the benzoquinone reagent, the cannabinoid mixture, and the reaction temperature; such that the THC content of the cannabinoid mixture is reduced to a greater extent than that of at least one of the one or more non-THC cannabinoids on a relative wt. % reduction basis.
The present technology generally relates to methods of making cocoa butter-derived products that comprise cannabinoids. The present technology further generally relates to cocoa butter-derived products resulting from such methods.
A23G 1/48 - Cocoa products, e.g. chocolateSubstitutes therefor characterised by the composition containing plants or parts thereof, e.g. fruits, seeds, extracts
A23G 1/36 - Cocoa products, e.g. chocolateSubstitutes therefor characterised by the composition characterised by the fats used
A23G 1/42 - Cocoa products, e.g. chocolateSubstitutes therefor characterised by the composition containing microorganisms or enzymesCocoa products, e.g. chocolateSubstitutes therefor characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
A23D 9/007 - Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
A23G 1/00 - CocoaCocoa products, e.g. chocolateSubstitutes therefor
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A23P 10/35 - Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
34.
METHODS FOR CONVERTING TETRAHYDROCANNABINOLIC ACID INTO CANNABINOLIC ACID
Disclosed herein is a method for converting tetrahydrocannabinolic acid (THCA) to cannabinolic acid (CBNA). The method comprises contacting an input material comprising THCA with a benzoquinone reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range; and (ii) a reaction time that is within a target reaction-time range, to provide an output material in which at least a portion of the THCA from the input material has been converted into CBNA.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
35.
Methods of synthesizing cannabigergol, cannabigerolic acid, and analogs thereof
Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
B01J 27/128 - HalogensCompounds thereof with iron group metals or platinum group metals
The present invention provides cannabinoid derivatives, a pharmaceutical composition comprising said derivative and a method of using said derivatives in treating or preventing a disease associated with cannabinoid receptors. The claimed cannabinoid derivatives are described by formula (I) or an enantiomer, diastereomer, racemate, tautomer, or metabolite thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound.
C07C 43/267 - Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing other rings
C07C 43/275 - Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings having all ether-oxygen atoms bound to carbon atoms of six-membered aromatic rings
C07C 43/315 - Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
C07C 65/28 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
C07C 69/28 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
C07C 69/96 - Esters of carbonic or haloformic acids
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
This disclosure relates to a cannabinoid derivative of formula (I), pharmaceutical composition thereof, and method of treating or preventing diseases associated with cannabinoid receptor in a subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.
This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.
C07F 9/6581 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
C07F 9/6571 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
C07F 9/6578 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and sulfur atoms with or without oxygen atoms, as ring hetero atoms
39.
IMPROVED METHODS FOR CONVERTING CANNABIDIOL INTO DELTA9-TETRAHYDROCANNABINOL UNDER PROTIC REACTION CONDITIONS
Disclosed herein is a method for converting cannabidiol (CBD) into a composition comprising Δ9-tetrahydrocannabinol (Δ9-THC) and Δ8-tetrahydrocannabinol (Δ8-THC) in which the composition has a Δ9-THC:Δ8-THC ratio of greater than 1.0:1.0. The method comprises contacting the CBD with a Lewis-acidic heterogeneous reagent under reaction conditions comprising: (i) a protic-solvent system; (ii) a reaction temperature that is less than a threshold reaction temperature for the Lewis-acidic heterogeneous reagent and the protic-solvent system; and (iii) a reaction time that is less than a threshold reaction time for the Lewis-acidic heterogeneous reagent, the protic-solvent system, and the reaction temperature.
Disclosed is a method for converting a first cannabinoid into a second cannabinoid that is a regioisomer of the first cannabinoid. The method comprises contacting the first cannabinoid with a Lewis-acidic heterogeneous reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range for the Lewis-acidic heterogeneous reagent and the first cannabinoid; and (ii) a reaction time that is within a target reaction-time range for the Lewis-acidic heterogeneous reagent, the reaction temperature, and the first cannabinoid.
Disclosed herein is a method for continuously preparing crystalline cannabinoid particles. The method includes preparing a cannabinoid-rich solution that comprises a first cannabinoid and inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid. The method includes flowing the cannabinoid-rich solution into a continuous stirred-tank reactor (CSTR) in a continuous manner, mixing the cannabinoid-rich solution under turbulent mixing conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the CSTR, and discharging the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution from the CSTR in a continuous manner to provide a flow rate through the CSTR. The method includes separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution in a continuous manner.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Disclosed herein is a method for producing crystalline cannabinoid particles in continuous mode. The method comprises preparing a cannabinoid-rich solution that comprises a first cannabinoid, and inducing the cannabinoid-rich solution to a supersaturated state in which the first cannabinoid has a supersaturated concentration that is greater than a corresponding saturation concentration of the first cannabinoid. The method further comprises flowing the cannabinoid-rich solution through a tubular reactor in a continuous manner under turbulent flow conditions to form a plurality of crystalline cannabinoid particles and a cannabinoid-depleted solution within the tubular reactor, and separating crystalline cannabinoid particles from the plurality of crystalline cannabinoid particles and the cannabinoid-depleted solution. The turbulent flow conditions are defined by a Reynold number that is greater than a critical Reynolds number for the cannabinoid-rich solution and the tubular reactor.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present disclosure relates to a cannabinoid derivative, a pharmaceutical composition comprising it, as well as its use in the treatment and prevention of diseases associated with a cannabinoid receptor in a subject in need thereof, such as acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, etc. The cannabinoid derivative has the following formula:
The present disclosure relates to a cannabinoid derivative, a pharmaceutical composition comprising it, as well as its use in the treatment and prevention of diseases associated with a cannabinoid receptor in a subject in need thereof, such as acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, etc. The cannabinoid derivative has the following formula:
This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in the treatment or prevention of a disease associated with a cannabinoid receptor, including receptors selected from CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 473/00 - Heterocyclic compounds containing purine ring systems
45.
METHODS FOR PREPARING CANNABINOIDS BY BASE-PROMOTED DOUBLE-BOND MIGRATION
Disclosed is a method for converting a first cannabinoid into a second cannabinoid that is a regioisomer of the first cannabinoid. The method comprising contacting the first cannabinoid with: (i) a base having a pKb that is less than a critical pKb for the first cannabinoid; and (ii) a solvent system comprising a polar solvent such as dimethyl sulfoxide (DMSO), triethylamine (TEA), or a combination thereof.
Disclosed herein a method for converting (cannabidiol) CBD into a composition comprising Δ8-tetrahydrocannabinol (Δ8-THC) and Δ9-tetrahydrocannabinol (Δ9-THC), in which the composition has a Δ8-THC:Δ9-THC ratio that is greater than 1.0:1.0. The method comprises contacting the CBD with a Lewis-acidic heterogeneous reagent under protic, aprotic, or neat reaction conditions comprising: (i) a reaction temperature that is greater than a threshold reaction temperature for the Lewis-acidic heterogeneous reagent and the solvent system; and (ii) a reaction time that is greater than a threshold reaction time for the Lewis-acidic heterogeneous reagent, the solvent system, and the reaction temperature.
There are provided compositions comprising a purified cannabidiol (CBD) or a derivative thereof and an anti-inflammatory botanical extract, and methods of use thereof for the management of pain in a subject.
A heater assembly for a vaporizer including a heat exchanger with an interior surface having at least one ridge and groove, and a heater positioned in the bore. An air management system for a vaporizer including a valve that allows air to be drawn through a valve inlet and pumped through a valve outlet with a pump or drawn through the valve outlet and inlet with external suction. A system and method for generating a workflow sequence for a vaporizer. The system and method including receiving task selections arranged in a task order, and generating a workflow sequence that is configured to instruct the vaporizer to sequentially perform the tasks associated with the task selections in the task order. A vaporizer that is configured to receive task selections arranged in a task order and sequentially perform the tasks associated with the task selections in the task order.
A vaporizer cartridge including a housing with at least one exterior wall and an interior dividing wall. An inlet extends through the exterior wall. The housing defines a payload reservoir, an inlet flow chamber in fluid communication with the inlet, and an outlet flow chamber in fluid communication with the inlet flow chamber. The interior dividing wall is positioned between the payload reservoir and the inlet flow chamber, and the inlet flow chamber is positioned between the exterior wall and the interior dividing wall. A vaporizer having a base and a cartridge as described above configured to removably couple to the base. At least one magnet may releasably couple the cartridge to the base. The cartridge may have an activation chamber separate from the payload reservoir and inlet and outlet flow chambers.
Disclosed herein is a method for converting cannabidiol (CBD) into a composition comprising Δ9-tetrahydrocannabinol (Δ9-THC) and Δ8-tetrahydrocannabinol (Δ8-THC) in which the composition has a Δ9-THC:Δ8-THC ratio of greater than 1.0:1.0. The method comprises contacting the CBD with a Lewis-acidic heterogeneous reagent under reaction conditions comprising: (i) an aprotic-solvent system; (ii) a reaction temperature that is less than a threshold reaction temperature for the Lewis-acidic heterogeneous reagent and the aprotic-solvent system; and (iii) a reaction time that is less than a threshold reaction time for the Lewis-acidic heterogeneous reagent, the aprotic-solvent system, and the reaction temperature. Methods for converting CBD into a composition comprising Δ9-THC and Δ8-THC in which the composition has a Δ9-THC:Δ8-THC ratio of greater than 1.0:1.0 under neat reaction conditions are also provided.
Disclosed herein is a cartridge for a vape device. The cartridge comprises a housing defining an inlet, an outlet, and an interior chamber that is position between the inlet and the outlet. The inlet, the outlet, and the interior chamber are fluidly connected by a flow path, and the inlet is configured to receive a first cannabinoid. The cartridge also comprises a Lewis-acidic heterogeneous reagent positioned in the interior chamber such that when the flow path passes through the interior chamber, at least a portion of the flow path contacts the Lewis-acidic heterogeneous reagent. The Lewis-acidic heterogeneous reagent has an acidity metric that surpasses a threshold acidity metric for the first cannabinoid such that contact between the Lewis-acidic heterogeneous reagent and the first cannabinoid under reaction conditions defined by a contact temperature and a contact time converts at least a portion of the first cannabinoid into a second cannabinoid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61M 11/04 - Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A24F 40/42 - Cartridges or containers for inhalable precursors
A24B 15/167 - Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
Disclosed herein is a method of converting a THC-rich cannabinoid mixture that comprises at least about 20% THC into a CBN-rich cannabinoid mixture that comprises at least about 2.0% CBN. The method comprises contacting the cannabinoid mixture with a benzoquinone reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range; and (ii) a reaction time that is within a target reaction-time range, such that at least a portion of the of the THC in the THC-rich cannabinoid mixture is converted into CBN.
The present technology generally relates to Cannabis plants having increased cannabichromenic acid (CBCA) and/or cannabichromene (CBC) content as well as to nucleic acids related to same and methods of producing same.
The present technology generally relates to Cannabis plants having increased cannabichromenic acid (CBCA) and/or cannabichromene (CBC) content as well as to nucleic acids related to same and methods of producing same.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Disclosed herein are methods for converting cannabidiol, cannabidiolic acid and analogs thereof into Δ8-tetrahydrocannabinol, Δ8-tetrahydrocannabinolic acid and analogs thereof. In particular, there is provided a method for converting a compound of Formula (I) as defined herein into a compound of Formula (II) as defined herein, the method comprising heating the compound of Formula (I) and a Lewis acidic heterogeneous reagent in an aprotic-solvent system to provide a compound of Formula (II), wherein the Lewis-acidic heterogeneous reagent is acidic alumina.
Disclosed are methods for synthesizing cannabielsoin (CBE) and or analogs thereof. In particular, the present disclosure provides methods for synthesizing CBE or analogs thereof comprising steps of providing a cannabinoid composition that comprises cannabidiol (CBD) or analogs thereof; combining the cannabinoid composition with an agent comprising a ketone functional group; and contacting the cannabinoid composition with an oxidizing agent or exposing the cannabinoid composition to electromagnetic radiation.
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
60.
CANNABINOID SALT COMPOUNDS AND METHODS OF MAKING SAME
Disclosed herein are cannabinoid salt compounds formed by mixing an acidic cannabinoid compound with a base. According to embodiments of the present disclosure, the base is selected at least for having a low toxicity. Also disclosed are methods of preparing cannabinoid salt compounds. Further, the present disclosure provides use of the cannabinoid salt compounds as an intermediate for isolating an ultra-high purity cannabinoid from a cannabis plant material or extract thereof.
C07C 65/19 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
B01J 27/128 - HalogensCompounds thereof with iron group metals or platinum group metals
Disclosed herein are cannabinoid salt compounds formed by mixing an acidic cannabinoid compound with a base. According to embodiments of the present disclosure, the base is selected at least for having a low toxicity. Also disclosed are methods of preparing cannabinoid salt compounds. Further, the present disclosure provides use of the cannabinoid salt compounds as an intermediate for isolating an ultra-high purity cannabinoid from a cannabis plant material or extract thereof.
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
C07C 65/19 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
The present technology generally relates to Cannabis plants having increased cannabigerolic acid (CBGA) and/or cannabigerol (CBG) content. The present technology also generally relates to isolated nucleic acids and isolated amino acids related to same and methods of producing same.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
64.
SYSTEM AND METHOD FOR AN IMPROVED PERSONAL VAPORIZATION DEVICE
A vape device system including a payload reservoir that is identified by a payload identifier and that is configured to hold a substance for atomization. A processor is configured to determine an operational setting based on at least one of the payload identifier and a secondary data, which may include user information, prescription information, location information, payload information, historical vape device usage information, and historical payload reservoir information. A vape device system, and method of using the same, that includes a vape device and a computing device that includes the processor. A method of controlling a vape device including determining an operational setting of the vape device based on the payload identifier and/or secondary data. The operational settings may include a duty cycle setting, a temperature setting, an operational time duration, a dosage setting, and a security setting.
This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heating material to a first temperature and a second temperature.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Disclosed are methods for preparing carmabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising CBG or the CBG analog. The method may further comprise separating the CBG or the CBG analog for the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a CBGA analog are also disclosed. The present disclosure also provides high purity CBG, CBGA and analogs thereof. CBG can be useful as a neuroprotectant, an antibacterial agent, etc.
C07C 51/09 - Preparation of carboxylic acids or their salts, halides, or anhydrides from carboxylic acid esters or lactones
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
C07C 37/16 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07C 65/19 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
This disclosure relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
This disclosure relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
25 - Clothing; footwear; headgear
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
31 - Agricultural products; live animals
32 - Beers; non-alcoholic beverages
34 - Tobacco; smokers' articles
35 - Advertising and business services
38 - Telecommunications services
40 - Treatment of materials; recycling, air and water treatment,
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Cosmetics, makeup, makeup removers, eye creams, skin care preparations, skin creams, skin serums, skin oils, skin emollients, skin lotions, non-medicated skin care treatment preparations, facial and body skin masks, skin soap, body powders for personal use, bath and shower soaps, liquid soap; face and body lotions, face and body milk, face lotion, hand cream, hand lotions, bath gels, bath lotions, non-medicated bath salts, bath scrubs, bath oils, bubble bath, bath additives, bath herbs, bath bombs, nail enamel and nail care preparations, nail polish remover, lip care preparations, lip conditioners, lip glosses, sun skin care preparations, sun screen preparations, sun block preparations, self-tanning preparations, after-sun skin soothing and moisturizing preparations, pre-shave and after shave lotions, pre-shave and after shave creams, pre-shave and after shave balms, pre-shave and after shave splashes, pre-shave and after shave gels, personal deodorants and antiperspirants, hair care preparations, hair oils, hair masks, scalp treatments, hair sunscreen preparations, non-medicated preparations for the care of the scalp, essential oils for aromatherapy, essential oils for perfumery and personal use, scented oils for personal use, massage creams; massage oils
(2) Medicated skincare products for the treatment of various conditions including psoriasis, cystic acne, acne, eczema, scars and wounds; topical skin creams, bar and liquid soaps, bath additives, bath herbs, bath oils, body creams, body oils, face and body lotions, face and body milk, face lotion, and other skin care preparations containing hemp, hemp derivatives, cannabis and derivatives of cannabis for the treatment of various conditions including psoriasis, cystic acne, acne, eczema, scars and wounds; pharmaceutical cannabis and cannabis derivative products and hemp and hemp derivative products for medicinal use including, oil extracts, oils, extracts, tinctures, resins, waxes, hashes, pastes, balms, salves, concentrates, lotions, sprays, ointments, pastes, extracts, tinctures, tonics, liquids, powders, teas, coffees, beverages, topical skin creams, lotions and gels, pills, tablets, capsules, suppositories, tampons, skin patches, sublingual doses, and mucous membrane doses, sprays and liquids, transdermal patches and oral sprays; botanical, herbal, nutraceutical, dietary and nutritional supplements, natural health products and natural solutions for general health and well-being; botanical, herbal, nutraceutical, dietary and nutritional preparations containing plant extracts and plant-derived nutrients; pharmaceutical, nutraceuticals, botanicals containing hemp, hemp derivatives, cannabis and derivatives of cannabis for therapeutic / medicinal use such as: general health and well-being, the temporary relief of joint and muscle pain, rheumatoid arthritis, nerve pain, weight loss, smoking cessation, hormonal imbalance indications including vaginal dryness, PMS (mensural relief), cramps, mental health (mood modulation, anxiety, relaxation, reducing stress, fatigue, mood enhancement, depression), insomnia / sleep aid, increase appetite; Veterinary preparations containing hemp, hemp derivatives, cannabis and cannabis derivatives for the treatment of diseases and disorders including, long-term neurogenic pain, muscle spasms, muscle cramps, reduced appetite, weight loss, treatment of pain and the induction of sedation, anxiety relief, and pain relief during therapeutic and diagnostic procedures
(3) Clothing, footwear and headwear
(4) Hemp, hemp derivatives, cannabis and cannabis derivative and infused products, not for medicinal use, including, oil extracts, oils, extracts, tinctures, resins, waxes, hashes, pastes, balms, salves, concentrates, lotions, sprays, ointments, tonics, liquids, powders, teas, coffees, beverages, topical skin creams, lotions and gels, pills, tablets, capsules, suppositories, tampons, skin patches, sublingual doses, mucous membrane doses, sprays and liquids, transdermal patches and oral sprays; hemp protein powder, hemp hearts, hemp oil, hemp seeds, hemp flour, hemp cereal, hemp milk, hemp-based snack foods and other hemp products
(5) Food products and edibles containing hemp, hemp derivatives, cannabis, cannabis extracts, cannabis resins, cannabis oils, cannabis gum, cannabis waxes, cannabis butters, and cannabis hashes and other derivatives including teas, cakes, cereal bars, cookies, pastries, brownies, muffins, cupcakes, bread, buns, biscuits, pastries, chocolate, chocolate confectionery and bars, chewing gum, energy bars, granola based bars, fruit bars, snack and food bars, meal replacement bars, dietary supplements, dietary supplements for promotion weight loss, sugar confectionery, gummies, hard candies, mints, crackers, granola, cereal, ice cream, candies, chewing gum, chips; Food and edible treats for pets containing hemp, hemp derivatives, cannabis, cannabis extracts, cannabis resins, cannabis oils, cannabis gum, cannabis waxes, cannabis butters, and cannabis hashes and other cannabis derivatives
(6) Cannabis in its various forms including live cannabis plants, cannabis seeds, fresh cannabis, dried cannabis; live plants and seeds for horticultural purposes; hemp in various forms
(7) Non-alcoholic beverages infused with hemp, hemp derivatives, cannabis, cannabis extracts, cannabis resins, cannabis oils, cannabis tinctures, cannabis waxes and other cannabis derivatives including smoothies, fruit beverages and fruit juices, carbonated soft drinks, and energy drinks and waters, protein supplement shakes, sports recovery drinks, isotonic drinks, dietary supplement drinks, meal replacement drinks; hemp smoothies, hemp fruit beverages, hemp fruit juices, carbonated soft drinks with hemp, hemp energy drinks and other hemp beverages
(8) Cannabis accessories for the preparation, use and storage of cannabis including water pipes, vaporizers, bongs, bowls, hookah, rolling papers, blunts, roach clips, pill bottles, lighters, torches, ashtrays, grinders, weighing scales; smokers' articles, namely, smoking pipes, pouches for use with cannabis, lighters for smokers; smokers' articles, namely, oral vaporizers for smokers; cannabis and marijuana for recreational use; derivatives of cannabis; hemp and hemp derivatives (1) Retail, online and wholesale sale in the following fields including hemp, hemp derivatives, recreational and medical cannabis, recreational and medical marijuana, cannabis derivative products, cannabis infused products including food, beverages, skin care products, pharmaceutical products, natural health products, and accessories, including pipes, rolling papers, water pipes, grinders, vaporizers, scales, bongs, bowls, hookah, blunts, roach clips, lighters, torches, ashtrays; Development, management and operation of businesses including advisory services in the healthcare industry, the medical marijuana and cannabis industry, the marijuana and cannabis industry and high-technology industry; advice and information concerning commercial business management; business management supervision; business planning
(2) Operation of an online bulletin board for publishing of information about benefits of hemp, medical marijuana and cannabis, research related to hemp, medical cannabis and marijuana and for users to provide commentary about the content or about subjects relating thereto; operation of an online bulletin board for registered users to participate in discussions, provide and obtain feedback from other registered users, form virtual communities, and engage in social networking in the field of hemp, medical marijuana and medical cannabis
(3) Educational services and patient educational services, including, audio, visual and print materials, seminars, workshops, classes, training sessions, computer applications and community events in various fields including healthcare, hemp, cannabis, medical marijuana, medical cannabis, cannabis strains, pharmaceutical products, natural health products, skincare products and therapeutic skincare products, case studies and patient information
(4) Operation of a medical and recreational cannabis dispensary; Operation of a website providing information on medical marijuana and medical cannabis, their related strains, cannabis infused products, related products and derivative products, hemp, hemp derivatives and products containing hemp and hemp derivatives; operation of a website providing information on research related to medical marijuana and medical cannabis; operation of a website providing information featuring the ratings, reviews and recommendations on recreational cannabis, medical marijuana and medical cannabis products and cannabis infused, related and derivative products, hemp and hemp derivatives and products containing hemp and hemp derivatives; operation of a website providing information regarding indications and effects of particular cannabis strain; Providing online directory information services relating to, among other things, medical cannabis, medical marijuana and related, infused and derivative products and hemp, hemp derivatives and products containing hemp and hemp derivatives; Consulting services including in the fields of medical use of marijuana, cannabis and their derivatives and infused products and hemp and hemp derivatives; Scientific research and development in the field of hemp, hemp derivatives, medical marijuana, medical cannabis, marijuana, cannabis, their related products and derivatives for the development of therapeutics, and to target specific symptoms, diseases, illnesses and disorders; Membership services and customer and patient loyalty services; Cultivating, breeding, growing, production, processing, distribution and development of marijuana and cannabis; import and export of marijuana and cannabis and their related and derivative products to Government approved sources in other countries
A charging structure for a vaporizer. The charging structure includes a housing, a first electrical contact coupled to and extending outward from a first end of the housing, a spacer coupled to the first electrical contact, and a second electrical contact coupled to and extending outward from the spacer. The first electrical contact includes an exposed outer surface that extends in a continuous loop. The second electrical contact includes an exposed side surface that extends in a continuous loop and an end surface coupled to the side surface. Both the side surface and the end surface are electrically conductive. A vaporizer including the charging structure.
The present invention is directed to a vape device configured to determine a dose of a vaporized payload delivered to a user during each of a plurality of user inhalations. The vape device includes a payload reservoir configured to contain a payload to be vaporized, as well as a heater or atomizer configured to vaporize a portion of the payload to thereby generate a vaporized payload during each respective user inhalation. The vape device also includes a piezoelectric sensor positioned within the air flow chamber and configured to mechanically vibrate at a frequency that is dependent on a natural frequency of the piezoelectric sensor as shifted by a mass of the vaporized payload deposited on a surface of the piezoelectric sensor. The vape device additionally incudes a frequency measurement circuit configured to obtain a frequency measurement corresponding to the frequency of the piezoelectric sensor. The vape device further includes a microcontroller programmed to determine a dose of the vaporized payload for each respective user inhalation based on one or more frequency measurements obtained for the user inhalation.
Compositions having enhanced cannabichromene (CBC) and abnormal cannabichromene (CBCab) concentrations are disclosed herein as are methods of synthesizing CBC and CBCab. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) provide product mixtures with enhanced CBCab concentrations; (iii) provide CBC at higher yield; (iv) provide easier to purify product mixtures comprising CBC; (v) provide product mixtures that comprise unique ratios of CBCab relative to other cannabinoids; and/or (vi) provide product mixtures with reduced THC concentrations.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
83.
METHODS OF SYNTHESIZING HIGH-PURITY CANNABICYCLOL AND ARTIFICIAL RESINS COMPRISING CANNABICYCLOL
Compositions having enhanced cannabicyclol (CBL) or CBL derivative concentrations are disclosed herein as are methods of synthesizing CBL and CBL derivative in high-purity form. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid extracts, isolates and/or distillates; (iii) provide CBL and/or CBL derivative at higher yield; (iv) provide easier methods to purify product mixtures comprising CBL and/or CBL derivative; (v) provide product mixtures that comprise unique ratios of CBL or CBL derivative relative to other cannabinoids; (vi) provide product mixtures with reduced THC concentrations and/or (vii) provide artificial resins having of a mixture cannabinoids that cannot be produced by extracting cannabis plant material.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
85.
CANNABICITRAN COMPOSITIONS AND METHODS OF SYNTHESIZING CANNABICITRAN
Compositions having enhanced cannabicitran concentrations and/or enhanced cannabicitran-derivative concentrations are disclosed herein as are methods of synthesizing cannabicitran and/or cannabicitran derivatives. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid isolates and/or distillates; (iii) provide cannabicitran and/or cannabicitran derivatives at higher yield; (iv) provide easier to purify product mixtures comprising cannabicitran and/or cannabicitran derivatives; (v) provide product mixtures comprising cannabicitran or cannabicitran derivatives that are easier to purify; (vi) provide product mixtures that comprise unique ratios of cannabicitran or cannabicitran derivatives relative to other cannabinoids; and/or (vii) provide product mixtures with reduced THC concentrations.
Compositions having enhanced cannabicyclol (CBL) or CBL derivative concentrations are disclosed herein as are methods of synthesizing CBL and CBL derivative in high-purity form. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid extracts, isolates and/or distillates; (iii) provide CBL and/or CBL derivative at higher yield; (iv) provide easier methods to purify product mixtures comprising CBL and/or CBL derivative; (v) provide product mixtures that comprise unique ratios of CBL or CBL derivative relative to other cannabinoids; (vi) provide product mixtures with reduced THC concentrations and/or (vii) provide artificial resins having of a mixture cannabinoids that cannot be produced by extracting cannabis plant material.
Compositions having enhanced cannabicitran concentrations and/or enhanced cannabicitran-derivative concentrations are disclosed herein as are methods of synthesizing cannabicitran and/or cannabicitran derivatives. Relative to conventional methods, the methods of the present disclosure may: (i) be better suited to large-scale conditions in that they do not require dangerous and/or toxic solvents and/or reagents; (ii) be more tolerant of complex starting compositions, such as cannabinoid isolates and/or distillates; (iii) provide cannabicitran and/or cannabicitran derivatives at higher yield; (iv) provide easier to purify product mixtures comprising cannabicitran and/or cannabicitran derivatives; (v) provide product mixtures comprising cannabicitran or cannabicitran derivatives that are easier to purify; (vi) provide product mixtures that comprise unique ratios of cannabicitran or cannabicitran derivatives relative to other cannabinoids; and/or (vii) provide product mixtures with reduced THC concentrations.
Water-soluble formulations including cannabinoids or a cannabis-derived compound for use in beverages and foods, methods of preparing the formulations, and methods of preparing beverages and foods including the formulations are disclosed herein. In some embodiments, the water-soluble formulations comprise a cannabinoid or a cannabis-derived compound; an emulsifier comprising Quillaja saponins; a carrier oil, and a glycerin-based carrier surfactant.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/25 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
C07C 43/295 - Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
C07C 69/33 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
C07C 69/96 - Esters of carbonic or haloformic acids
The present application discloses a compound of formula (I): compositions comprising said compound, and a method of using said compound as a cannabinoid receptor ligand in the treatment or prevention of diseases associated with a cannabinoid receptor, such as, CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR119, TRPV1, TPRV2, PPARγ or a μ-opioid receptor.
The synthesis of a range of pentylbezene- 1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors. Accordingly, the use of such synthetic cannabinoids in the treatment of various disorders mediated by CB1 and CB2 is contemplated.
C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07C 309/42 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
C07C 309/75 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
C07C 317/22 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07C 317/24 - SulfonesSulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
C07C 205/06 - Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
C07C 205/12 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
C07D 207/408 - Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 277/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R12322, R2is methyl, R3is CsHn, R4is -C(O)N(R4a)(R4b), R5is H, R6is OH, and R7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.
C07C 235/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
C07C 235/56 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
C07C 271/20 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 203/16 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07D 215/14 - Radicals substituted by oxygen atoms
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 235/12 - Radicals substituted by oxygen atoms
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 277/24 - Radicals substituted by oxygen atoms
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
in-situin-situin-situin-situin-actioin-actio concentration that is greater than the saturation concentration of the cannabinoid-based target component. As such, the cannabinoid-based vape oil has a high-effective concentration of the cannabinoid-based target component.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
C07C 65/19 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
C07D 311/78 - Ring systems having three or more relevant rings
A charging structure for a vaporizer. The charging structure includes a housing, a first electrical contact coupled to and extending outward from a first end of the housing, a spacer coupled to and extending outward from the first electrical contact, and a second electrical contact coupled to and extending outward from the spacer. The first electrical contact includes an exposed outer surface that extends in a continuous loop. The second electrical contact includes an exposed side surface that extends in a continuous loop and an end surface coupled to the side surface. Both the side surface and the end surface are electrically conductive. A vaporizer including the charging structure.
A charging structure for a vaporizer. The charging structure includes a housing, a first electrical contact coupled to and extending outward from a first end of the housing, a spacer coupled to the first electrical contact, and a second electrical contact coupled to and extending outward from the spacer. The first electrical contact includes an exposed outer surface that extends in a continuous loop. The second electrical contact includes an exposed side surface that extends in a continuous loop and an end surface coupled to the side surface. Both the side surface and the end surface are electrically conductive. A vaporizer including the charging structure.
